Roche's Diagnostic Foothold Gives Genentech A Leg Up In Oncology
This article was originally published in The Pink Sheet Daily
Executive Summary
Research to be presented at American Society of Clinical Oncology meeting shows role of biomarkers for lead compounds, including vemurafenib, MetMAb and Tarceva.
You may also be interested in...
Roche Could Repeat Genentech Success With Foundation Medicine Partnership
Foundation Medicine gets a $400 million cash infusion to continue its cancer diagnostic R&D while Roche acquires a majority interest in the company and will use its products to guide and optimize its clinical trials for cancer immunotherapies.
Roche’s Onartuzumab Failure Raises More Questions About How Best To Target Met
Roche’s onartuzumab (MetMab) fails in Phase III lung cancer study, raising questions about the company’s biomarker approach and the Met target more generally.
Roche’s Onartuzumab Failure Raises More Questions About How Best To Target Met
Roche’s onartuzumab (MetMab) fails in Phase III lung cancer study, raising questions about the company’s biomarker approach and the Met target more generally.